Nefiracetam CAS NO.77191-36-7

Product introduction

Nefiracetam belongs to the non-borderline intelligence enhancing class of drugs, which have different chemical structures and enhance cognitive ability and prevent the damage of learning and memory through their effects on the cerebral cortex. It does not have the properties of muscarinic receptor agonists and antagonists, nor does inhibit the activity of Ach. The anti-forgetting and memory-enhancing effects of this drug are achieved by enhancing the release of Ach in the cerebral cortex. Camp-dependent protein kinases enhance Ca2+ channel activity, which may be responsible for their enhanced Ach release. Nefiracetam (NEF) is a pyrrolidone type nootropic agent with various pharmacologic as well as cognition enhancing effects. In amygdala-kindled seizures, nefiracetam inhibits both electroencephalographic and behavioral seizures. NEF has a distinct anticonvulsant spectrum.

Features

Nefiracetam is used to treat cerebrovascular diseases. It can enhance the cognitive ability and prevent the damage of learning and memory by its effect on the cerebral cortex. It does not have the properties of muscarinic receptor agonist and antagonistic agent, nor does it inhibit the activity of acetyl cholinase . Therefore, its anti-forgetting and memory-enhancing effects occur by improving the release of acetylcholine in the cerebral cortex.

Applications

Nefiracetam is a hydrophobic derivative of piracetam and a synthetic synthesis of all Racetam compounds piracetam. Nefiracetam is manufactured primarily by Daiichi Sankyo (Japanese pharmaceutical company) for the treatment of AD. In addition to all the mechanisms attributed to Nefiracetam， it is generally thought to be a substance that is responsible for the discovery of calcium channels in the body, as well as the indirect transfer of the excitation signaling substance, acting as a partial agonist of the glycine-binding site of the NDMA receptor.